Severe Asthma in Children - PowerPoint PPT Presentation

1 / 44
About This Presentation
Title:

Severe Asthma in Children

Description:

Severe Asthma in Children. Andrew Bush MD FRCP FRCPCH. Imperial ... Bronchoscope on history alone; record is 25 years undiagnosed! Treatment of Difficult Asthma ... – PowerPoint PPT presentation

Number of Views:1802
Avg rating:5.0/5.0
Slides: 45
Provided by: Bush54
Category:

less

Transcript and Presenter's Notes

Title: Severe Asthma in Children


1
Severe Asthma in Children
  • Andrew Bush MD FRCP FRCPCH
  • Imperial School of Medicine
  • Royal Brompton Hospital

email a.bush_at_imperial.ac.uk
2
Preliminary Steps
  • Is it asthma at all?
  • Is it a steroid sensitive asthma?
  • Are they taking the treatment?
  • CAN they take the treatment?
  • Dysfunctional breathing?

3
Asthma The Basics
  • Most children with asthma are easily treated
  • Most respond to modest ICS doses, and get no
    benefit from high doses
  • High dose ICS may be harmful
  • What makes this childs asthma different and
    difficult to treat?

4
Definitions
  • Difficult to treat asthma becomes easy when the
    basics are got right (adherence, environment,
    etc.)
  • Really severe asthma treatment still extremely
    difficult despite getting the basics right

5
Treatment of Difficult Asthma
  • Is the diagnosis correct?
  • Is the drug delivery device appropriate?
  • Are there important environmental issues?
  • Are there important psychological issues
  • What is the pathological phenotype?

6
(No Transcript)
7
Endobronchial Foreign Body
  • Very sudden onset of symptoms
  • Ask specifically about the possibility of choking
    or aspiration
  • Listen for abnormal signs asymetric, fixed
    monophonic wheeze Signs MAY be bilateral, or
    absent
  • CXR may be normal
  • Bronchoscope on history alone record is 25 years
    undiagnosed!

8
(No Transcript)
9
Treatment of Difficult Asthma
  • Is the diagnosis correct?
  • Is the drug delivery device appropriate?
  • Are there important environmental issues?
  • Are there important psychological issues
  • What is the pathological phenotype?

10
Is the drug going to the right place?
11
Correct use of the nebuliser a tight fitting
mask is essential
12
Treatment of Difficult Asthma
  • Is the diagnosis correct?
  • Is the drug delivery device appropriate?
  • Are there important environmental issues?
  • Are there important psychological issues
  • What is the pathological phenotype?

13
Steroid Resistance 2ry to Environmental Smoke
exposure?
  • I never smoke in front of the children, Dr!
  • Their dad smokes, but only outside!

14
Cigarette smoke induced, 2ry steroid resistance
  • FP 1000 mcg/day vs. placebo
  • Steroid naïve asthmatics
  • COPD excluded BDR, positive Mch
  • Lower sputum eosins (3.8 0.7-5.5 vs. 0.3
    0.0-0.9) in smokers
  • PEFR, BHR, sputum induction

Thorax 2002 57 226-30
15
Steroid Resistance 2ry to Allergens
  • He is no worse when the cat is around, Dr!
  • I took the cat away for 2 weeks, and he was no
    better!
  • Honey the kids are allergic to the cat we had
    better get rid of the kids!

16
(No Transcript)
17
(No Transcript)
18
Dose-response curves for inhibition of PHA
stimulation. White no IL-2 or 4 Black IL-2
IL-4 IL-2 IL-4 decrease sensitivity to the
anti-proliferative effects of dexamethasone
19
Am J Respir Crit Care Med 2007 176 20-6
20
Treatment of Difficult Asthma
  • Is the diagnosis correct?
  • Is the drug delivery device appropriate?
  • Are there important environmental issues?
  • Are there important psychological issues
  • What is the pathological phenotype?

21
Flow volume loop Marked attenuation of
inspiratory flow rates
22
Treatment of Difficult Asthma
  • Is the diagnosis correct?
  • Is the drug delivery device appropriate?
  • Are there important environmental issues?
  • Are there important psychological issues
  • What is the pathological phenotype?

23
Patterns of Difficulty in Asthma
  • Near fatal asthma which may recur despite
    adequate treatment
  • Brittle asthma
  • Sudden dips on a background of good control
  • Persistently labile peak flow
  • Persistent symptoms despite high dose therapy

24
Components of the Asthma Phenotype
  • Bronchial hyper-reactivity
  • Airway inflammation
  • Best achievable airway calibre target lung
    function

25
The Difficult Asthma Protocol
  • Visit two FOB
  • Assess reversible factors
  • Assess symptoms,
  • use of rescue medication
  • Spirometry, PC20, reversibility
  • Induced sputum, eNO
  • FOB, BAL, biopsy

Intramuscular Triamcinolone
  • Visit one MDT Assessment
  • Drug delivery device
  • Home visit environment
  • School visit bullying?
  • Assess compliance
  • Psychological assessment

1-2 months
4-6 weeks
  • Visit three Decision time
  • Assess symptoms, diary card,
  • and use of rescue medication
  • Spirometry, PC20, reversibility
  • Induced sputum, eNO
  • Serum cortisol assay

26
Visit One Team Assessment
  • Home visit
  • Environment pets, tobacco exposure
  • Use of devices
  • Adherence medicines not found, out of date, in
    original wrapping
  • GP visit
  • Prescriptions dispensed
  • School Visit
  • School absences
  • Bullying
  • 50 Need No Further Action

27
Endobronchial Biopsy
28
  • Histology can be very variable
  • Normal
  • Eosinophilia
  • Neutrophilia
  • Mixed cellularity

29
Phenotype Specific Asthma Treatment
  • Steroid sensitive (eosinophilic) inflammation
  • Normal lung function, normal sputum FeNO, no
    BHR on Visit 3
  • Usually eosinophilic inflammation on visit 2
    biopsy
  • Treatment approach
  • Wean steroids
  • (Cyclosporin A if intolerable side-effects)

30
Phenotype Specific Asthma Treatment
  • Steroid resistant eosinophilic inflammation (1)
  • Symptomatic
  • Eosinophilic biopsy on visit 2, no triamcinolone
    response (sputum, FeNO)
  • (steroid receptor abnormalities)
  • Treatment approach
  • Look for causes of steroid resistance
  • Cyclosporin A
  • Other steroid sparing agent

31
Steroid Resistance
  • Congenital
  • Low receptor numbers
  • Normal binding affinity
  • Very rare
  • Acquired
  • Normal or high receptor numbers
  • Reduced binding affinity
  • Common

32
Secondary Steroid ResistanceWhat to Do?
  • Eliminate not asthma at all
  • CF, foreign body
  • Eliminate asthma plus
  • Rhinitis, GERD
  • Eliminate Difficult Asthma
  • Detailed multidisciplinary assessment

33
Phenotype Specific Asthma Treatment
  • Steroid resistant eosinophilic inflammation (2)
  • No symptoms on Visit 3
  • Eosinophilic biopsy on visit 2, eosinophilic
    sputum visit 3
  • Treatment approach
  • Await events
  • Eosinophils not always the bad guy

34
Is Inflammation Always Bad?
Control
MBP Staining
Asthma in remission
BlueJ 2001 164 2107-13
35
Phenotype Specific Asthma Treatment
  • Neutrophilic inflammation
  • Symptomatic throughout
  • Neutrophilic inflammation on visit 2 biopsy
  • Persistent sputum neutrophilia, visit 3
  • Treatment approach
  • Theophyllines (neutrophil apoptosis)
  • Macrolides (reduced epithelial IL-8)
  • 5-Lipoxygenase inhibitor (LTB4) or LTB4 receptor
    antagonist
  • Smoking??

36
Phenotype Specific Asthma Treatment
  • BHR, no inflammation
  • Symptomatic throughout
  • Marked PF variability and reversibility
    throughout
  • No inflammation on visit 3 sputum visit 2 biopsy
    may be variable
  • Treatment approach
  • Subcutaneous terbutaline infusion
  • (Increase dose of LABs)

37
Continuous subcutaneous infusion of terbutaline
- CSIT
  • IV preparation (0.5 mg/ml)
  • Graseby pump, 90 Thalaset needle
  • Dose - 5 mg/day
  • smaller child 2.5 mg / day
  • maximum 10 mg / day
  • Start as in-patient
  • Ideally n1 trial, with saline also
  • Payne et al, Ped Pulmonol 2002

38
Effect of subcutaneous terbutaline on peak flow
Pediatr Pulmonol 2002
39
Inflammation in Severe Asthma
  • Sputum induction (3.5 saline) in 40 children,
    symptomatic despite gt 1 mg FP/day
  • Two excluded as FEV1 lt 65 all given ß-2 agonist
    prior to procedure
  • 28/38 (74) sample obtained

40
Inflammation in Severe Asthma
  • 7/38 symptomatic during induction, only 3 ? FEV1
    gt -20
  • Only 9/28 had persistent inflammation
  • 6 eosinophilic (eosins gt 2.5)
  • 3 non-eosinophilic (neutrophils gt 54)

Conclusion inflammation apparently not that
common
41
Phenotype Specific Asthma Treatment
  • Fixed airflow obstruction
  • Symptomatic throughout
  • Obstructive spirometry, no reversibility
    throughout
  • No inflammation on visit 2 biopsy
  • Treatment approach
  • Reduce treatment until evidence of reversibility
    appears
  • Uusually able to stop all therapy (Obliterative
    bronchiolitis)

42
Obliterative bronchiolitis ?post adenoviral
infection
43
Summary and Conclusions
  • Do not forget the obvious
  • Wrong diagnosis
  • Not taking treatment
  • Cannot use device
  • Ask the key question What makes this asthma
    difficult?
  • Consider environmental causes of steroid
    resistance
  • Only then think of escalating therapy

44
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com